Evidence map›Paper›PMID 36015073›Full record

ArticlePharmaceuticals (Basel, Switzerland)2022

Citicoline Modifies the Expression of Specific miRNAs Related to Cardioprotection in Patients with ST-Segment Elevation Myocardial Infarction Subjected to Coronary Angioplasty.

Alejandro Silva-Palacios, Miguel Arroyo-Campuzano, Mirthala Flores-García, Mariana Patlán, Adrián Hernández-Díazcouder, Diego Alcántara, Ixchel Ramírez-Camacho, Dana Arana-Hidalgo, Elizabeth Soria-Castro, Fausto Sánchez and 2 more

Open access · goldAbstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Caveolin and NOS in the Development of Muscular Dystrophy.International journal of molecular sciences · 2024
    Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Alejandro Silva-PalaciosDepartamento de Biomedicina Cardiovascular, Instituto Nacional de Cardiología Ignacio Chávez, Juan Badiano No. 1, Colonia Sección XVI, México City 14080, Mexico.ORCID 0000-0002-8409-7967
Miguel Arroyo-CampuzanoDepartamento de Biomedicina Cardiovascular, Instituto Nacional de Cardiología Ignacio Chávez, Juan Badiano No. 1, Colonia Sección XVI, México City 14080, Mexico.
Mirthala Flores-GarcíaDepartamento de Biología Molecular, Instituto Nacional de Cardiología, Ignacio Chávez, Juan Badiano No. 1, Colonia Sección XVI, México City 14080, Mexico.
Mariana PatlánSubdirección de Investigación Básica y Tecnológica, Instituto Nacional de Cardiología, Ignacio Chávez, Juan Badiano No. 1, Colonia Sección XVI, México City 14080, Mexico.
Adrián Hernández-DíazcouderDepartamento de Inmunología, Instituto Nacional de Cardiología, Ignacio Chávez, Juan Badiano No. 1, Colonia Sección XVI, México City 14080, Mexico.ORCID 0000-0001-6569-2851
Diego AlcántaraDepartamento de Biomedicina Cardiovascular, Instituto Nacional de Cardiología Ignacio Chávez, Juan Badiano No. 1, Colonia Sección XVI, México City 14080, Mexico.
Ixchel Ramírez-CamachoDepartamento de Biomedicina Cardiovascular, Instituto Nacional de Cardiología Ignacio Chávez, Juan Badiano No. 1, Colonia Sección XVI, México City 14080, Mexico.
Dana Arana-HidalgoDepartamento de Biomedicina Cardiovascular, Instituto Nacional de Cardiología Ignacio Chávez, Juan Badiano No. 1, Colonia Sección XVI, México City 14080, Mexico.
Elizabeth Soria-CastroDepartamento de Biomedicina Cardiovascular, Instituto Nacional de Cardiología Ignacio Chávez, Juan Badiano No. 1, Colonia Sección XVI, México City 14080, Mexico.
Fausto SánchezDepartamento de Inmunología, Instituto Nacional de Cardiología, Ignacio Chávez, Juan Badiano No. 1, Colonia Sección XVI, México City 14080, Mexico.
Héctor González-PachecoUnidad Coronaria, Instituto Nacional de Cardiología Ignacio Chávez, México City 14080, Mexico.
Cecilia ZazuetaDepartamento de Biomedicina Cardiovascular, Instituto Nacional de Cardiología Ignacio Chávez, Juan Badiano No. 1, Colonia Sección XVI, México City 14080, Mexico.ORCID 0000-0003-1068-316X
Instituto Nacional de Cardiología · MX

Funding

Consejo Nacional de Ciencia y Tecnología 283363
6 · The paper itself

Abstract

Extracellular vesicles are recognized as signaling mediators between cells both in physiological and pathological communication. In this work, we explored the potential effect of citicoline to modify relevant proteins or miRNAs for cardioprotection in the smallest population of such microvesicles; i.e., in exosomes from patients diagnosed with ST-segment elevation myocardial infarction (STEMI) undergoing coronary angioplasty. The plasma-exosome-enriched fraction from these patients was characterized. Their cellular origin was assessed by flow cytometry and Western blot, whereas miRNA expression was evaluated by real-time polymerase chain reaction (qRT-PCR). The content of caveolin-1, caveolin-3, and hnRNPA2B1, which play a relevant role in selective transport of miRNAs into microvesicles, along with the effect on cell viability of the exosomes obtained from citicoline-treated and untreated groups were also analyzed. Our results showed that hypoxic stress increases exosome release into the circulation. Moreover, we found that CD146+ increased in exosomes from citicoline-treated patients, while CD142+ decreased in these patients compared to the placebo group. No changes were detected in the protein levels of caveolin-1, caveolin-3, and hnRNPA2B1. Citicoline administration modified the expression of miR233-3p, miR92, and miR21-5p in exosomes. Cell viability decreased in the presence of exosomes from infarcted patients, while incubation of H9c2 cells with exosomes from patients reperfused with citicoline did not affect cell viability. In conclusion, citicoline administration modifies the expression of specific miRNAs related to cardioprotection in exosomes.

Indexed as

cardiac biomarkercaveolin-1caveolin-3citicolineexosomeshnRNPA2B1miRNAsreperfusion therapySTEMI

Identifiers

PMID36015073
PMCPMC9413952
OpenAlexW4288905186

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.